Target 2035 – an update on private sector contributions

Ackloo, Suzanne; Antolín, Albert A.; Bartolomé, José M.; Beck, Hartmut; Bullock, Alex N.; Betz, Ulrich; Boêttcher, J.; Brown, Peter J.; Chaturvedi, Menorca; Crisp, Alisa; Daniels, Danette L.; Dreher, Jan; Edfeldt, Kristina; Edwards, A.M.; Egner, Ursula; Elkins, Jon; Fischer, Christian; Glendorf, Tine; Goldberg, Steven D.; Hartung, Ingo V.; Hillisch, Alexander; Homan, Evert; Knapp, Stefan; Köster, Markus; Krämer, Oliver; Llaveria, Josep; Lessel, Uta; Lindemann, Sven; Linderoth, Lars; Matsui, Hisanori; Michel, Maurice; Montel, Florian; Mueller‐Fahrnow, Anke; Müller, Susanne; Owen, Dafydd R.; Saikatendu, Kumar Singh; Santhakumar, V.; Sanderson, Wendy; Scholten, Cora; Schapira, Matthieu; Sharma, Sujata; Shireman, Brock T.; Sundström, M.; Todd, Matthew H.; Tredup, Claudia; Venable, Jennifer D.; Willson, Timothy M.; Arrowsmith, C.H.

doi:10.1039/d2md00441k

Cited by 4 publications

(2 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the chemical coverage of the human proteome remains far from complete, achieving this ambitious goal by year 2035 remains possible thanks to the continuous scientific, technical, and logistical progress of the Target 2035 community. 2,3,8 To accelerate the clinical impact of this global effort, we propose that a focus should be brought on proteins involved in biological pathways enriched in drugs and deprived of chemical tools, as was highlighted in this analysis. Another valid but longer-term strategy is to focus on chemically underexplored pathways, ones so far devoid of both drugs and chemical tools.…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3] To accelerate the characterization of the human proteome, biomedical scientists around the globe have formed a federation called Target 2035 to develop and openly provide rigorously characterized chemical tools, such as chemical probes and chemogenomic compounds, for the entire druggable human proteome by year 2035. 2,3,8 Target 2035 contributors include, but are not limited to, the Structural Genomics Consortium (SGC) 9 , EUbOPEN 10 , RESOLUTE 11 , NCATS at NIH 12 , Boehringer Ingelheim's opnMe 13 , and portals such as Chemical Probes Portal 14 , Pharos 15 , Probes and Drugs 16 , and ChemBioPort 17 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Chemical Coverage of the Human Reactome

Kwak,

Liu,

Tredup

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Chemical probes and chemogenomic compounds are valuable tools to link gene to phenotype, explore human biology and uncover novel targets for precision medicine. A growing federation of scientists is contributing to the mission of Target 2035 - discovering chemical tools for all druggable human proteins by the year 2035. It is expected that these compounds will enable the understanding of the regulation of cellular machineries and biological processes across the compendium of signaling pathways that animate cellular life. Here, we draw a landscape of the current chemical coverage of the human Reactome. We find that even though available chemical probes and chemogenomic compounds are targeting only 3% of the human proteome, they cover 53% of the human Reactome, due to the fact that 46% of human proteins are involved in more than one cellular pathway. As such, existing chemical probes and chemogenomic compounds already represent a versatile toolkit to manipulate a vast portion of human biology. Pathways targeted by existing drugs may be enriched in unknown but valid drug targets and could be prioritized in future Target 2035 efforts.

show abstract

Section: Discussionmentioning

confidence: 99%